The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Open-label phase II study of everolimus plus endocrine therapy in postmenopausal women with ER+, HER2- metastatic breast cancer (Chloe trial).
 
Tadahiko Shien
Consulting or Advisory Role - Allergan; AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Kyowa Kirin; Lilly; Novartis; Pfizer; Taiho Pharmaceutical; Takeda
Speakers' Bureau - Allergan; AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Kyowa Kirin; Lilly; Nihonkayaku; Novartis; Pfizer; Taiho Pharmaceutical; Takeda
Research Funding - Eisai (Inst); Nihonkayaku (Inst)
 
Masahiro Kitada
No Relationships to Disclose
 
Yukari Uemura
Honoraria - Chugai Pharma; Teijin Pharma
Consulting or Advisory Role - Daiichi Sankyo Pharmaceutical; Ono Pharmaceutical; Pfizer; Zeria Pharmaceutical
Speakers' Bureau - Pfizer
Travel, Accommodations, Expenses - Chugai Pharma; Daiichi Sankyo Pharmaceutical
 
Hiroaki Kato
No Relationships to Disclose
 
Yuichiro Kikawa
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo/UCB Japan; Eisai; Lilly Japan; Novartis; Pfizer; Taiho Pharmaceutical
 
Akihiko Shimomura
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo/UCB Japan; Eisai; Kyowa Kirin International; Lilly; MSD K.K; Novartis; Pfizer
Consulting or Advisory Role - AstraZeneca; Lilly Japan; Pfizer
Research Funding - AstraZeneca (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Mochida Pharmaceutical Co. Ltd. (Inst); Taiho Pharmaceutical (Inst)
 
Kenichi Watanabe
No Relationships to Disclose
 
Yasuyuki Kojima
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Kyowa Hakko Kirin; Lilly Japan; Pfizer; Taiho Pharmaceutical
Research Funding - Chugai Pharma (Inst)
 
Toru Yokota
No Relationships to Disclose
 
Yoshiaki Kamei
No Relationships to Disclose
 
Reiki Nishimura
Honoraria - Lilly O.; Pfizer
 
Takeshi Nagashima
No Relationships to Disclose
 
Naoki Hashimoto
No Relationships to Disclose
 
Koichi Sakaguchi
No Relationships to Disclose
 
Toshinari Yamashita
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Kyowa Hakko Kirin; Lilly; Nippon Kayaku; Novartis; Pfizer; Taiho Pharmaceutical
Research Funding - Chugai Pharma (Inst); Kyowa Hakko Kirin (Inst); Nihonkayaku (Inst); Taiho Pharmaceutical (Inst)
 
Kenichi Harano
Honoraria - AstraZeneca; Chugai Pharma; Eisai; MSD K.K; Takeda
Consulting or Advisory Role - AstraZeneca; Chugai Pharma; Lilly O.; Takeda
Research Funding - Daiichi Sankyo Pharmaceutical; Merck
 
Kan Yonemori
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo/Astra Zeneca; Eisai; Fujifilm; Lilly Japan; MSD Oncology; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Chugai Pharma; Eisai; Novartis; OncXerna Therapeutics; Ono Pharmaceutical
Research Funding - AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Eisai (Inst); Genmab (Inst); Haihe Pharmaceutical (Inst); Kyowa Hakko Kirrin (Inst); Lilly (Inst); MSD (Inst); Nihonkayaku (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Sanofi (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Takeda (Inst); Takeda (Inst)
 
Yoshiya Horimoto
No Relationships to Disclose
 
Hirofumi Mukai
Honoraria - Daiichi Sankyo; Taiho Pharmaceutical; Takeda